论文部分内容阅读
目的比较荧光原位杂交(FISH)和免疫组化(IHC)检测乳腺癌组织中人表皮生长因子受体2(HER-2)基因扩增及蛋白表达的一致性,并探讨HER-2基因扩增与临床病理特征的关系。方法回顾性分析本院采用FISH法检测HER-2基因状态的112例乳腺癌,与IHC结果进行一致性分析,并对HER-2基因扩增与年龄、组织学分级、淋巴结转移及激素受体的关系进行统计学分析。结果 112例浸润性乳腺癌中,HER-2基因扩增57例,其中IHC检测HER-2(3+)者27例,(2+)者29例,(1+)者1例,分别占IHC病例总数的96.4%(27/28)、48.3%(29/60)和5.3%(1/19)。HER-2基因扩增与雌/孕激素受体呈负相关,而与年龄、组织学分级、淋巴结转移差异不显著。结论对于IHC检测HER-2(3+)、(+或0)的病例可选择性做FISH进行确认,对于HER-2(2+)病例应常规进行FISH检测,以便更加准确和客观地对治疗和预后进行评价。
Objective To compare the amplification of the human epidermal growth factor receptor 2 (HER-2) gene and the protein expression in breast cancer by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) Increased and clinicopathological characteristics of the relationship. Methods The clinical data of 112 cases of breast cancer with HER-2 gene status detected by FISH in our hospital were analyzed retrospectively. The consistency of IHC results with HER-2 gene amplification and age, histological grade, lymph node metastasis and hormone receptor The relationship between the statistical analysis. Results There were 57 cases of HER-2 gene amplification in 112 cases of invasive breast cancer, including 27 cases of HER-2 (3+) detected by IHC, 29 cases of (2+) and 1 case of (1+) 96.4% (27/28), 48.3% (29/60) and 5.3% (1/19) of the total IHC cases. HER-2 gene amplification and estrogen / progesterone receptor was negatively correlated, but with age, histological grade, lymph node metastasis was no significant difference. Conclusions FISH can be selectively confirmed in cases of IHC for HER-2 (3 +), (+ or 0), and FISH should routinely be performed in cases of HER-2 (2+) for more accurate and objective treatment And prognosis.